Cromolyn Metal Complexes for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cromolyn sodium (CS) exhibits low bioavailability and poor absorption due to its high solubility and low permeability when orally administered, limiting its therapeutic effectiveness in treating allergic diseases.
Innovation Solution
The formation of 3D flexible pharmaceutical metal complexes (pMCs) by coordinating cromolyn with bioactive metals like Zn2+, Mg2+, and Ca2+, which enhance stability, bioavailability, and therapeutic efficacy by forming crystalline structures that can be designed for controlled particle size and prolonged circulation to the target site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cromolyn sodium is administered orally, then it can be delivered systemically, but its bioavailability is low and absorption is poor due to high solubility and low permeability
Solution Approach 1:
The patent forms metal coordination complexes by combining cromolyn sodium with metal ions (Ca2+, Mg2+, Zn2+). These composite metal-complex formulations improve intestinal absorption and bioavailability compared to cromolyn sodium alone, directly addressing the low bioavailability issue while maintaining oral administration feasibility
Solution Approach 2:
The patent alters the chemical and physical parameters of cromolyn sodium by forming coordination complexes with metals. This changes the molecular structure and properties of the drug, transforming it from a form with low permeability and poor absorption to one with enhanced intestinal absorption and systemic bioavailability
2Speed
If cromolyn is administered intranasally, then it can deliver therapeutic effect quickly, but it causes irritation to the nasal mucosa
Solution Approach 1:
The patent uses metal coordination complexes as intermediary forms of cromolyn. These complexes modify the drug's properties to reduce direct irritation to nasal mucosa while maintaining therapeutic efficacy, allowing intranasal administration to proceed with fewer harmful side effects
3Reliability
If cromolyn is administered transdermally, then it can bypass first-pass metabolism, but its self-aggregation tendency complicates permeation control
Solution Approach 1:
The patent changes the physical-chemical parameters of cromolyn by forming metal complexes. This modification reduces self-aggregation tendency and improves transdermal permeation characteristics, making the permeation profile more controllable while maintaining high bioavailability
Solution Approach 2:
By creating composite metal-complex formulations, the patent modifies cromolyn's aggregation behavior and permeation properties. These composite materials provide more predictable and controllable transdermal delivery while bypassing first-pass metabolism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting Cromolyn-based pMCs demonstrate improved stability and slow release profiles, achieving higher bioavailability and therapeutic effectiveness with reduced adverse side effects, potentially offering a novel multi-drug delivery system for allergic and inflammatory diseases.
Implementation Method 1
cromolyn (FIG. 1) is employed as a ligand, which in coordination with bioactive metals, form a series of 3D flexible metal complexes denominated as pharmaceutical metal complexes (pMCs)
Implementation Method 2
the synthesis and characterization of the resulting Cromolyn-based pMCs is discussed as well as their stability and dissolution in FaSSGF (pH=1.60) and PBS (pH=7.40) at 37° C.
Data Source
AI summary
A series of pharmaceutical metal complexes (pMCs) were produced and characterized using the mast cell stabilizer, cromolyn, and bioactive metal ions (Zn+2, Mg+2, and Ca+2). Three novel pMCs, Cromolyn-Zn, Cromolyn-Mg, and Cromolyn-Ca were formed through reactions under controlled temperature and pH conditions. TGA demonstrated that these metal complexes showed an enhanced thermal stability due to the strong coordination with the ligand, cromolyn. PXRD data indicates a high degree of crystallinity as well as a unique packing arrangement for each pMCs. SEM analysis showed materials with well-defined morphologies while EDS presented elemental evidence for the unique composition of each pMCs. The crystal structure for these materials was elucidated through SCXRD, and a variety of binding modes and packing motifs were found within each respective metal complex. Only 2D structures were achieved under the conditions studied. Dissolution studies show high stability and slow degradation for the metal complexes, while a higher dissolution was observed for the drug compound in PBS. Neither CS nor the pMCs dissolved significantly in FaSSGF at 37° C.